2018
DOI: 10.1038/s41598-018-33498-5
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The human papillomavirus (HPV) is present in a significant fraction of head-and-neck squamous cell cancer (HNSCC). The main goal of this study was to identify distinct co-expression patterns between HPV+ and HPV− HNSCC and to provide insights into potential regulatory mechanisms/effects within the analyzed networks. We selected cases deposited in The Cancer Genome Atlas database comprising data of gene expression, methylation profiles and mutational patterns, in addition to clinical information. The intersecti… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
25
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(26 citation statements)
references
References 70 publications
1
25
0
Order By: Relevance
“…Among the key prognostic markers for survival, epidermal growth factor receptor (EGFR), cyclin D1(CCND1), ERCC1, p16, human papillomavirus (HPV), and B‐cell lymphoma‐extra large (Bcl‐xL)/Bcl‐2, as well as the amplification of genes including EMS1 , FGFR1 , and CCND1 have demonstrated some evidence in clinical trials. Others are slower to advance in clinical development because of unconvincing data and few published studies; for example, acetylcholinesterase(AchE), SNPs of specific genes, glutathione S‐transferase (GST), CD44, amplification of specific genes, hypoxic markers, KLK‐6, and MDA‐7/IL‐24; although, this does not preclude them from future investigations and clinical utility.…”
Section: Biomarkers In Hnscc Tumor Tissuesmentioning
confidence: 99%
“…Among the key prognostic markers for survival, epidermal growth factor receptor (EGFR), cyclin D1(CCND1), ERCC1, p16, human papillomavirus (HPV), and B‐cell lymphoma‐extra large (Bcl‐xL)/Bcl‐2, as well as the amplification of genes including EMS1 , FGFR1 , and CCND1 have demonstrated some evidence in clinical trials. Others are slower to advance in clinical development because of unconvincing data and few published studies; for example, acetylcholinesterase(AchE), SNPs of specific genes, glutathione S‐transferase (GST), CD44, amplification of specific genes, hypoxic markers, KLK‐6, and MDA‐7/IL‐24; although, this does not preclude them from future investigations and clinical utility.…”
Section: Biomarkers In Hnscc Tumor Tissuesmentioning
confidence: 99%
“…This gene is downregulated in HPV induced tumors. SPRR2G shows downregulation in HPV-positive cases as compared with HPVnegative cases (Costa et al, 2018).…”
Section: Small Proline-rich Protein 2g (Sprr2g)mentioning
confidence: 86%
“…This gene is significantly downregulated and shows more methylation in HPV-negative HNSCC (Costa, Boroni, & Soares, 2018).…”
Section: Gap-junction Beta-6 Protein (Gjb6)mentioning
confidence: 98%
“…Another point of emphasis derived from the present overview is the growing integration among omics data obtained on the same cohort of patients. Even if these experiences are still limited for HNSCC and in terms of types of omics employed and amount of published studies [23,27,43,58,66,76], these initiatives enabling to better dissect cancer complexity deserve further investigations. Moreover, we can expect that new approaches based on artificial intelligence will be available in the next future dealing with more complex data even integrating multi-omics layers [94].…”
Section: Discussionmentioning
confidence: 99%